The latest price target for Cytokinetics (NASDAQ:CYTK) was reported by RBC Capital on July 7, 2026. The analyst firm set a price target for $117.00 expecting CYTK to rise to within 12 months (a possible 42.80% upside). 48 analyst firms have reported ratings in the last year.

The latest analyst rating for Cytokinetics (NASDAQ:CYTK) was provided by RBC Capital, and Cytokinetics maintained their outperform rating.

The last upgrade for Cytokinetics Inc happened on June 29, 2026 when UBS raised their price target to $115. UBS previously had a neutral for Cytokinetics Inc.

There is no last downgrade for Cytokinetics.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Cytokinetics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Cytokinetics was filed on July 7, 2026 so you should expect the next rating to be made available sometime around July 7, 2027.

While ratings are subjective and will change, the latest Cytokinetics (CYTK) rating was a maintained with a price target of $119.00 to $117.00. The current price Cytokinetics (CYTK) is trading at is $81.93, which is out of the analyst’s predicted range.